Literature DB >> 25858771

Increased radiation dose heterogeneity within the prostate predisposes to urethral strictures in patients receiving moderately hypofractionated prostate radiation therapy.

Andrew M McDonald1, Christopher B Baker2, Richard A Popple3, Rex A Cardan3, John B Fiveash3.   

Abstract

PURPOSE: The purpose of this study was to determine whether radiation dose inhomogeneity within the prostate predisposes to late urinary strictures after moderately hypofractionated definitive external beam radiation therapy for prostate cancer. METHODS AND MATERIALS: One hundred seventy-three men with clinically localized prostate cancer met the inclusion criteria for this analysis. All patients received 70 Gy to the prostate delivered over 28 fractions, had at least 2 years of clinical follow-up, and had dose-volume histogram information available for review. The endpoint of this study was the development of a urethral stricture that required a procedural intervention such as urethral dilation or suprapubic catheterization. Dosimetric parameters were evaluated for effect on the rate of urethral stricture formation by univariate Cox proportional hazards modeling.
RESULTS: The median follow-up was 49.5 months (range, 24.6-108 months). At 5 years, the actuarial rate of intervention for urethral strictures across all patients was 4.9%. The maximum point dose within the prostate (P = .034, hazard ratio = 1.006) and the mean prostate dose (P = .039, hazard ratio = 1.004) were the only parameters predictive of urethral stricture formation. All patients who developed a urethral stricture were treated by a plan with a maximum prostate dose of >75 Gy (median, 77.67 Gy).
CONCLUSIONS: For patients receiving moderately hypofractionated prostate radiation therapy over 28 fractions, a maximum point dose of 75 Gy within the prostate was associated with an increased probability of developing a urethral stricture that required procedural intervention. The hypothesis that hypofractionation increases susceptibility to toxicity from heterogeneity within the prostate should be confirmed by analyzing data from randomized trials with a conventionally fractionated control arm for comparison.
Copyright © 2015 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25858771     DOI: 10.1016/j.prro.2015.02.010

Source DB:  PubMed          Journal:  Pract Radiat Oncol        ISSN: 1879-8500


  4 in total

1.  Prostate Stereotactic Body Radiation Therapy: An Overview of Toxicity and Dose Response.

Authors:  Kyle Wang; Panayiotis Mavroidis; Trevor J Royce; Aaron D Falchook; Sean P Collins; Stephen Sapareto; Nathan C Sheets; Donald B Fuller; Issam El Naqa; Ellen Yorke; Jimm Grimm; Andrew Jackson; Ronald C Chen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-12-22       Impact factor: 7.038

2.  A retrospective study of late adverse events in proton beam therapy for prostate cancer.

Authors:  Hirokazu Makishima; Hitoshi Ishikawa; Keiichi Tanaka; Yutaro Mori; Masashi Mizumoto; Kayoko Ohnishi; Teruhito Aihara; Nobuyoshi Fukumitsu; Toshiyuki Okumura; Hideyuki Sakurai
Journal:  Mol Clin Oncol       Date:  2017-08-11

3.  External Validation of a Predictive Model of Urethral Strictures for Prostate Patients Treated With HDR Brachytherapy Boost.

Authors:  Vanessa Panettieri; Tiziana Rancati; Eva Onjukka; Martin A Ebert; David J Joseph; James W Denham; Allison Steigler; Jeremy L Millar
Journal:  Front Oncol       Date:  2020-06-11       Impact factor: 6.244

Review 4.  Treatment of Urethral Strictures from Irradiation and Other Nonsurgical Forms of Pelvic Cancer Treatment.

Authors:  Iyad Khourdaji; Jacob Parke; Avinash Chennamsetty; Frank Burks
Journal:  Adv Urol       Date:  2015-10-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.